The Form 4 filing, an SEC report of insider stock trades, was filed on November 16, 2026. The sales took place on November 13, 2026.
The 12 transactions were reported in one filing for one insider.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 12 |
| Shares Transacted | 9,500 |
| Price | $592.42 |
| Total Transaction Value | $5,627,991.42 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of UTHR stock, marked with transaction code S. The seller, Martine A. Rothblatt, is United Therapeutics' chairperson and CEO.
What was the average price of the transaction?
The average price was $592.42 per share across the 12 sales. The available details do not list a separate price for each sale.
How did this transaction affect the insider's holdings?
Martine A. Rothblatt sold 9,500 shares and reported 324,443 shares owned afterward. The shares sold made up 2.84% of the reported shares owned before the sales.
What's the total transaction value?
The total value of the 12 sales was $5,627,991.42.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 reference. Plans under this rule set trading instructions in advance.
Footnote text and plan terms are not available. It is unclear which of the 12 sales the reference covers, when a plan began, or what trading schedule it used. The reference alone does not confirm that the sales met the rule's legal requirements.
For research purposes only; not investment advice.